United StatesHealthcare and life sciences2025 – ongoingBio-Techne
AI engineering of commercial designer proteins
Bio-Techne launched designer proteins developed with generative AI and protein engineering
Problem
Cell therapy developers needed proteins with properties suited to cell culture and expansion. Relevant requirements included heat stability and receptor affinity.
Approach
Bio-Techne combined generative AI trained on its proteomic data with protein library evolution and rational design. Its R&D Systems business launched additional designer proteins, including heat-stable growth factors. The products were commercially available for research and, for selected products, therapeutic development workflows.
Results
No published figures
Takeaway
Bio-Techne commercialized proteins developed through a combined computational and experimental workflow. It did not isolate AI's contribution or publish a quantified development benefit.
Categories
- Industry
- Healthcare and life sciences
- Business function
- IT and R&D
- Innovation type
- Product and service innovation
- AI technology
- Generative AI
- Adoption
- Built in-house
- Evidence
- Company's own claim
Sources
Source summaries
Bio-Techne announced an expanded commercial protein portfolio developed using generative AI and protein engineering. It described tailored biological activity and improved stability, without numerical performance comparisons.
Full details are in the original sources.